Clinical trial · Observational
Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning
A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions and Predict Biological Biomarker and Prognosis of Hepatocellular Carcinoma
NCT05257694CI-TRIAL-00061598unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ablation | — | UNRESOLVED | — |
| Contrast-enhanced Ultrasound | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Prognosis | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablation (Microwave ablation or Radiofrequency ablation) | Procedure | — | UNRESOLVED |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Recurrence-free survival (RFS)
- timeFrame
- Immediately after the surgery or ablation
- description
- Recurrence-free survival is defined as the time elapsed between a predefined point in time (the date of diagnosis, randomization or the intervention) and any recurrence (local, regional, or distant) or death due to any cause (death is an event).
Secondary outcomes (1)
- measure
- Recurrence
- timeFrame
- Immediately after the surgery or ablation
- description
- Recurrence included local tumor progression, regional recurrence, or distant recurrence.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with HCC (Ia, Ib, IIa stage) China liver cancer staging who underwent resection or ablation * without macro-vascular invasion * Child-Pugh A/B grade * HCC is proved by pathological examination or two enhanced imaging * CEUS (Sonovue or Sonozoid) images are performed two weeks before the operation * Invasive biomarker or prognosis of HCC available * CEUS images are included in at least three stages (Arterial phase, Portal phase, and Late phase) Exclusion Criteria: * postop follow-up loss or expired less than 3 months * patients with co-malignancy * poor images quality for analyzing
References
Publications (0)
Data not yet available
No reference posted for this study.